Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
Evaluation of novel cell cycle inhibitors in mantle cell lymphoma
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Evaluation of novel cell cycle inhibitors in mantle cell lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Styryl
100%
Sulfone
100%
Mantle Cell Lymphoma
100%
Cell Cycle Inhibitors
100%
Cytotoxicity
33%
Doxorubicin
33%
Apoptosis
16%
B-cell Lymphoma
16%
Lymphoma Cells
16%
Apoptotic Pathway
16%
Kinase Inhibitor
16%
Poly(ADP-ribose) Polymerase
16%
Cyclin
16%
Caspase-3 Activity
16%
Cyclin B
16%
Murine Double Minute 2 (MDM2)
16%
Purine
16%
End-labelling
16%
Transferases
16%
Molecular Analysis
16%
Novel Class
16%
Targeted Therapy
16%
Related Compounds
16%
New Drug Development
16%
Cyclin D
16%
Pyrimidine
16%
Uridine Triphosphate
16%
Cell Cycle Pathway
16%
Polymerase Assay
16%
Pharmacology, Toxicology and Pharmaceutical Science
Sulfone
100%
Mantle Cell Lymphoma
100%
Cytotoxicity
33%
Vincristine
33%
Doxorubicin
33%
Phosphotransferase Inhibitor
16%
Protein P53
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
16%
Cycline
16%
Drug Development
16%
Caspase 3
16%
Purine Derivative
16%
Transferase
16%
B Cell Lymphoma
16%
Uridine Triphosphate
16%
Cyclin B
16%
Pyrimidine Derivative
16%
Protein MDM2
16%
Cyclin D
16%